This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
| Yesterday’s UK 100 Leaders | Price (p) | % Chg |
| CARNIVAL PLC | 1,160.5 | 16.5% |
| CENTRICA PLC | 41.5 | 15.4% |
| BARCLAYS PLC | 110.2 | 12.7% |
| EVRAZ PLC | 278.0 | 12.6% |
| EASYJET PLC | 643.4 | 12.4% |
| Yesterday’s UK 100 Laggards | Price (p) | % Chg |
| POLYMETAL INTERNATIONAL PLC | 1646.0 | -1.7% |
| OCADO GROUP PLC | 1625.0 | -1.6% |
| CRODA INTERNATIONAL PLC | 4936.0 | -0.8% |
| RECKITT BENCKISER GROUP PLC | 6402.0 | -0.8% |
| GLAXOSMITHKLINE PLC | 1677.0 | -0.6% |
| Major World Indices | Price | % Chg | 1 Year |
| UK 100 INDEX | 6,115 | 2.6% | -17.8% |
| DOW JONES INDUS. AVG | 24,634 | 2.2% | -7.2% |
| DAX INDEX | 11,108 | 2.9% | -9.9% |
| NIKKEI 225 | 19,771 | -0.1% | -11.2% |
| S&P/ASX 200 INDEX | 5,393 | 1.5% | -14.7% |
| Commodities | Units | Price | % Chg |
| WTI Crude Oil (Nymex) | USD/bbl. | 15.50 | 25.61% |
| Brent Crude (ICE) | USD/bbl. | 22.87 | 11.78% |
| Gold Spot | USD/t oz. | 1,713 | 0.3% |
| Copper (Comex) | USd/lb. | 238 | 1.4% |
Click graph to enlarge
UK 100 called to open +36 points points at 6160. The positive momentum continued last night as Asian stocks rose to seven week highs, mainly encouraged by positive early results from a COVID-19 treatment trial. Gilead sciences lead the pack with this positive trial breakthrough. The ECB have a new conference today (1.30pm) where they are expected to expand their bond buying programme to better support banks. Elsewhere Germany's COVID cases increased the most on four days whilst the US sizes up lock down options and underscores a second-wave risk. WTI crude surged last night continuing its recovery to finish at $16.61 a barrel.
GlaxoSmithKline have released that the FDA have cleared their expanded use of their drug Zejula as a first option to keep advanced ovarian cancer at bay in women who have responded to chemotherapy.
Glencore have slashed their 2020 spending and production guidance as coronavirus hits trading. Capital expenditure will fall by $1-1.5bn, whilst copper production fell -9% and colbat production slid -44%.
Lloyds scrapes a Q1 2020 pretax profit of £74m (2019: £1.6bn) after announcing £1.4bn of provisions against expected bad loans due to the coronavirus pandemic. This profit figure was sharply below the £863m average of analysts forecasts compiled by the bank.
Reckitt Benckiser have posted record sales on disinfectant boom. Q1 2020 sales rose +13.3% beating analysts' estimates of +5.3%.
Royal Dutch Shell cuts their dividend for first time since 1940s as oil demand collapses. They have cut their dividend to 16 cents per share from 47 cents per share previously.
Sainsbury's warns that coronavirus costs could hit £500m and said it would defer any dividend payment decisions until later in the financial year.
St James's Place cuts its dividend as Q1 2020 Assets Under Management (AUM) falls. They've reported that their AUM fell 2% to £101.7bn and they are to withold 11.22p of its final 2019 dividend, but will pay 20p per share as a second 2019 interim dividend on 27th May 2020.
Royal Dutch Shell B
Sainsbury
Schroders
St James Place
Evraz
Lloyds
Royal Bank Of Scotland
CN - Non Manufacturing PMI
US - Initial Jobless Claims
EU - Consumer Price Index (CPI)
EU - Gross Domestic Product (GDP)
EU - ECB Interest Rate Decision
UK 100 :
London Stock Exchange Group
:
Ferrexpo
Centemin
Derwent London
Lloyds target price decreased by Morgan Stanley to 50p (Bloomberg: 16 Buy/7 Holds/ 3 Sells)
JD Weathespoon upgraded by Stifel to Hold(Bloomberg: 16 Buy/7 Holds/ 3 Sells)
Plus 500 target price increased by Berenberg to 1120p (Bloomberg: 1 Buy/1 Holds/ 2 Sells)
Anglo American downgraded by Morningstar to 1120p (Bloomberg: 14 Buy/9 Holds/ 1 Sells)
Astrazeneca target price increased by HSBC to 6690p (Bloomberg: 21 Buy/6 Holds/ 4 Sells)
For any help you may require placing trades or in terms of market information, put a call in to our trading floor – it’s all part of the service.
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.